---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-006255"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2022-03-15T23:59:59+00:00"
generated_at: "2026-06-26T22:59:29.379745+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q3 revenue record $13.2M, up 22% YoY; adj. EBITDA $1.5M

## Summary
- Revenue of $13.2M for quarter ended Jan 31, 2022, a 22% increase from $10.8M in prior year.
- Adjusted EBITDA was $1.5M; net income from operations of $830K (incl. $310K stock comp).
- Gross margin for Q3 was 51.4% vs 57.2% a year ago; nine-month gross margin improved to 51.9% from 48.8%.
- Cash position $8.7M with no debt; signed co-development partnerships with Fannin Innovation Studio and Gigamune.
- Company reaffirms FY2022 revenue growth guidance of 15%-20%.

## SEC filing metadata
- accession: 0001628280-22-006255
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2022-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828022006255/0001628280-22-006255-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828022006255/csbr-20220315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-006255
- JSON: https://secwatch.observer/filing/0001628280-22-006255.json
- Plain text: https://secwatch.observer/filing/0001628280-22-006255.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.